Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

In vitro inhibition of SARS virus replication by human interferons.

Identifieur interne : 000E35 ( Ncbi/Curation ); précédent : 000E34; suivant : 000E36

In vitro inhibition of SARS virus replication by human interferons.

Auteurs : Helena Dahl [Suède] ; Annika Linde ; Orjan Stranneg Rd

Source :

RBID : pubmed:15764169

Descripteurs français

English descriptors

Abstract

Four different types of human interferon, interferon-beta (IFN-beta), recombinant IFN-alpha2a and IFN-alpha2b and natural IFN-alpha were tested for antiviral activity against SARS-coronavirus. The experiments were performed using in vitro cultivated monkey Vero E6 cells. IFN-beta was found to be the most highly active antiviral agent, followed by natural IFN-alpha, whereas the 2 recombinant IFN-alpha2 species were poorly active in the system used. These results suggest that IFN-beta as well as natural IFN-alpha may be used for the treatment of SARS.

DOI: 10.1080/00365540410021144
PubMed: 15764169

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:15764169

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">In vitro inhibition of SARS virus replication by human interferons.</title>
<author>
<name sortKey="Dahl, Helena" sort="Dahl, Helena" uniqKey="Dahl H" first="Helena" last="Dahl">Helena Dahl</name>
<affiliation wicri:level="3">
<nlm:affiliation>Swedish Institute for Infectious Disease Control, Stockholm, Sweden. Helena.Dahl@smi.ki.se</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Swedish Institute for Infectious Disease Control, Stockholm</wicri:regionArea>
<placeName>
<settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Linde, Annika" sort="Linde, Annika" uniqKey="Linde A" first="Annika" last="Linde">Annika Linde</name>
</author>
<author>
<name sortKey="Stranneg Rd, Orjan" sort="Stranneg Rd, Orjan" uniqKey="Stranneg Rd O" first="Orjan" last="Stranneg Rd">Orjan Stranneg Rd</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15764169</idno>
<idno type="pmid">15764169</idno>
<idno type="doi">10.1080/00365540410021144</idno>
<idno type="wicri:Area/PubMed/Corpus">002845</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002845</idno>
<idno type="wicri:Area/PubMed/Curation">002845</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002845</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002C47</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C47</idno>
<idno type="wicri:Area/Ncbi/Merge">000E35</idno>
<idno type="wicri:Area/Ncbi/Curation">000E35</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">In vitro inhibition of SARS virus replication by human interferons.</title>
<author>
<name sortKey="Dahl, Helena" sort="Dahl, Helena" uniqKey="Dahl H" first="Helena" last="Dahl">Helena Dahl</name>
<affiliation wicri:level="3">
<nlm:affiliation>Swedish Institute for Infectious Disease Control, Stockholm, Sweden. Helena.Dahl@smi.ki.se</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Swedish Institute for Infectious Disease Control, Stockholm</wicri:regionArea>
<placeName>
<settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Linde, Annika" sort="Linde, Annika" uniqKey="Linde A" first="Annika" last="Linde">Annika Linde</name>
</author>
<author>
<name sortKey="Stranneg Rd, Orjan" sort="Stranneg Rd, Orjan" uniqKey="Stranneg Rd O" first="Orjan" last="Stranneg Rd">Orjan Stranneg Rd</name>
</author>
</analytic>
<series>
<title level="j">Scandinavian journal of infectious diseases</title>
<idno type="ISSN">0036-5548</idno>
<imprint>
<date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Chlorocebus aethiops</term>
<term>Humans</term>
<term>Interferon alpha-2</term>
<term>Interferon-alpha (pharmacology)</term>
<term>Interferon-beta (pharmacology)</term>
<term>Recombinant Proteins</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (physiology)</term>
<term>Vero Cells</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Cellules Vero</term>
<term>Humains</term>
<term>Interféron alpha (pharmacologie)</term>
<term>Interféron bêta (pharmacologie)</term>
<term>Protéines recombinantes</term>
<term>Réplication virale ()</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Antiviral Agents</term>
<term>Interferon-alpha</term>
<term>Interferon-beta</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>SARS Virus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Antiviraux</term>
<term>Interféron alpha</term>
<term>Interféron bêta</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr">
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Humans</term>
<term>Interferon alpha-2</term>
<term>Recombinant Proteins</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Cellules Vero</term>
<term>Humains</term>
<term>Protéines recombinantes</term>
<term>Réplication virale</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Four different types of human interferon, interferon-beta (IFN-beta), recombinant IFN-alpha2a and IFN-alpha2b and natural IFN-alpha were tested for antiviral activity against SARS-coronavirus. The experiments were performed using in vitro cultivated monkey Vero E6 cells. IFN-beta was found to be the most highly active antiviral agent, followed by natural IFN-alpha, whereas the 2 recombinant IFN-alpha2 species were poorly active in the system used. These results suggest that IFN-beta as well as natural IFN-alpha may be used for the treatment of SARS.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E35 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000E35 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:15764169
   |texte=   In vitro inhibition of SARS virus replication by human interferons.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:15764169" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021